AbbVie (ABBV) - Stock Price & Dividends

Exchange: USA Stocks • Country: United States • Currency: USD • Type: Common Stock • ISIN: US00287Y1091

Pharmaceuticals, Therapeutics, Injections, Medications, Treatments

AbbVie Inc. is a global pharmaceutical company that discovers, develops, manufactures, and sells a wide range of medications and therapies to treat various diseases and conditions. The company's portfolio includes some well-known brands such as Humira, Skyrizi, Rinvoq, and Imbruvica, which are used to treat autoimmune diseases, cancer, and other conditions.

Apart from its pharmaceutical products, AbbVie also offers a range of facial injectables, plastics, and regenerative medicine products, as well as body contouring and skincare products. The company's botox therapeutic products are used to treat a variety of conditions, including facial wrinkles and migraines.

In addition to its pharmaceutical and aesthetics products, AbbVie also offers a range of eye care products, including Ozurdex, Lumigan, and Restasis, which are used to treat eye diseases and conditions such as glaucoma and dry eye syndrome.

The company's product portfolio also includes treatments for hepatitis C, irritable bowel syndrome, and hypothyroidism, among other conditions. AbbVie has collaborations with several other companies, including Calico Life Sciences, REGENXBIO, Janssen Biotech, and Genentech, to develop new and innovative treatments for various diseases.

AbbVie was incorporated in 2012 and is headquartered in North Chicago, Illinois. The company is committed to developing innovative medicines and therapies that improve the lives of patients around the world. With its strong research and development pipeline and collaborations with other companies, AbbVie is well-positioned to continue to make significant contributions to the field of healthcare.

Drawdown (Underwater) Chart

Drawdown / Underwater Chart for AbbVie (ABBV) - Stock Price & Dividends

Overall Trend and Yearly Seasonality

Drawdown / Underwater Chart for AbbVie (ABBV) - Stock Price & Dividends

ABBV Stock Overview

Market Cap in USD 283,334m
Sector Healthcare
Industry Drug Manufacturers - General
GiC SubIndustry Biotechnology
TER 0.00%
IPO / Inception 2013-01-02

ABBV Stock Ratings

Growth 5y 8.79
Fundamental 31.6
Dividend 8.69
Rel. Performance vs Sector 1.08
Analysts 3.81/5
Fair Price Momentum 154.49 USD
Fair Price DCF 339.78 USD

ABBV Dividends

Yield 12m 3.90%
Yield on Cost 5y 9.91%
Dividends CAGR 5y 6.70%
Payout Consistency 100.0%

ABBV Growth Ratios

Growth 12m 18.47%
Growth Correlation 12m 61%
Growth Correlation 3m -62%
CAGR 5y 20.47%
CAGR/Mean DD 5y 2.72
Sharpe Ratio 12m 0.72
Alpha vs SP500 12m -1.76
Beta vs SP500 5y weekly 0.66
ValueRay RSI 4.74
Volatility GJR Garch 1y 20.02%
Price / SMA 50 -6.88%
Price / SMA 200 -0.62%
Current Volume 5533.5k
Average Volume 20d 4881.7k

External Links for ABBV Stock

Wall Street JournalBenzingaYahoo Finance
Fund Manager Positions
What is the price of ABBV stocks?
As of May 30, 2024, the stock is trading at USD 155.34 with a total of 5,533,467 shares traded.
Over the past week, the price has changed by -4.66%, over one month by -3.83%, over three months by -11.92% and over the past year by +18.47%.
What are the forecast for ABBV stock price target?
According to ValueRays Forecast Model, ABBV AbbVie will be worth about 168.8 in May 2025. The stock is currently trading at 155.34. This means that the stock has a potential upside of +8.64%.
Issuer Forecast Upside
Wallstreet Target Price 183.2 17.9
Analysts Target Price 160.2 3.14
ValueRay Target Price 168.8 8.64

AbbVie Inc: Bridging Innovation and Healthcare

History of AbbVie

AbbVie Inc's journey began in 2013, following its separation from Abbott Laboratories. The split allowed AbbVie to focus intensively on research-based pharmaceutical manufacturing, evolving rapidly into a biopharmaceutical giant. The creation of AbbVie was aimed at dedicating resources and efforts towards innovative drug development, addressing complex and serious health issues worldwide.

Core Business

At the heart of AbbVie's mission is its commitment to developing pharmaceuticals that make a significant impact on patients' lives. The company focuses on key therapeutic areas including Immunology, Oncology, Neuroscience, and Virology. AbbVie is renowned for its blockbuster drug, Humira, used in treating various autoimmune diseases. However, the company is not resting on its laurels and is heavily investing in research and development to explore new treatments and expand its portfolio. Leveraging advanced science and expertise, AbbVie aims for breakthroughs that offer new hope to patients.

Side Business and Diversification

Apart from its primary pharmaceutical ventures, AbbVie has been expanding its footprint through strategic acquisitions, enhancing its research capabilities and therapeutic areas. Notably, the acquisition of Allergan in 2020, a notable player in the aesthetics and dermatology sector, broadened AbbVie's product range beyond traditional pharmaceuticals. Such movements underscore AbbVie’s strategy to diversify its portfolio and reinforce its market presence in various healthcare sub-sectors.

Current Market Status

As of the latest updates, AbbVie continues to hold a robust position in the global pharmaceutical market. It is known for its dynamic approach to growth, strategic partnerships, and a consistent track record of successful drug development. Financial markets reflect confidence in AbbVie’s potential for sustained growth, underpinned by its innovative pipeline and strategic business decisions. Despite the competitive nature of the pharmaceutical industry, AbbVie’s commitment to addressing unmet medical needs keeps it at the forefront of healthcare innovation.